Из чего изготовлена гиалуроновая кислота?

Гиалуроновая кислотаis also known as hyaluronic acid. It is a viscous polysaccharide composed of (1-3)-2-acetamido-2-deoxy-β-D-glucose units linked by β-1,4 and β-1,3 glycosidic bonds, alternately connected with (1-4)-O-β-D-glucuronic acid units. Hyaluronic acid is a widely distributed polysaccharide molecule in nature that forms a viscoelastic substance when combined with water. In the human body, it is primarily found in skin and connective tissues, serving as an extracellular matrix. In addition to providing cells with water and volume, it possesses properties such as tissue stability, strong binding capacity, high viscoelasticity, weak species and tissue specificity, and lack of immunogenicity. Hyaluronic acid has widespread applications in drug delivery, anti-adhesion in orthopaedic surgery, cardiology, arthritis, cancer therapy, ophthalmology, and food supplements.

1 препарат гиалуроновой кислоты

1.1 метод экстракции тканей животных

В 1934 году мейер и др., профессора офтальмологии колумбийского университета в США, впервые изолировали это вещество от витального юмора коровьих глаз [1]. В 1970 - х годах балаз и др. извлекают гиалуроновую кислоту из куриных комбайнов и пуповинных ниток человека [1].

В настоящее времяmain process for extracting hyaluronic acid powder from animal tissues includes dehydration, grinding, soaking, extraction, purification, precipitation, and separation. The specific process is as follows: first, homogenise the tissue, then extract it with water and dilute salt solution. The extract is precipitated with chlorinated hexadecylpyridine or hexadecyl trimethylammonium bromide, The resulting precipitate is dissolved, the residue is removed, and the solution is precipitated with 2–3 times the volume of ethanol to obtain crude hyaluronic acid. Purification can be achieved by treating the crude product with ethanol or quaternary ammonium salts, or by further removing impurities and proteins using enzymatic hydrolysis, ultrafiltration, or ion exchange techniques, ultimately yielding the final product.

The tissue extraction method has the advantages of a simple process, high molecular weight, high viscosity, and strong moisturising properties. However, due to limitations in raw material availability and the coexistence of hyaluronic acid with other polysaccharides such as chondroitin sulfate in biological tissues, this method has low yield, poor separation, complex process, and high cost, making it unsuitable for large-scale production. It is more suitable for small-scale production with dispersed raw material sources. With the continuous increase in demand and application scope of hyaluronic acid, the animal tissue extraction method will inevitably be gradually replaced by other methods.

1.2 метод микробной ферментации

С 1970 - х годов исследователи начали использовать микробную ферментацию для производства гиалуроновой кислоты. Представитель японии сисейдо впервые сообщил об использовании стрептококка equi для производства гиалуроновой кислоты в 1985 году. Наиболее распространенными бактериями, производящими гиалуроническую кислоту, являются, главным образом, группы A и C видов стрептококков, перечисленных в Bergey's Manual. The A group mainly includes Streptococcus pyogenes, which are pathogenic to humans and unsuitable as production strains; the C group of Streptococcus species are non-pathogenic to humans and more suitable for industrial production. In recent years, foreign countries have already achieved industrial-scale production of hyaluronic acid using C group Streptococcus species [2].

Operational process: Inoculate the slant culture into conical flasks containing culture medium, incubate at 37°C for 12–16 hours, then transfer to seed tanks. The nitrogen source in the culture medium is peptone, beef extract, yeast extract, etc., the carbon source is glucose, and the inoculation ratio is 1:10. The fermentation broth formulation is essentially the same as the seed broth, except that the glucose content is higher, typically 3%–6%. Maintain an aeration rate of 0.3–1.0 vvm (volume of air per minute relative to the fermentation volume), stir at 120 rpm, and ferment at 37°C for 40–46 hours. During fermentation, adjust the pH to 6.5–7.0. In the later stages of fermentation, when the glucose concentration drops below 0.5% and the pH decreases slowly or stops decreasing, fermentation is complete. After fermentation, adjust the pH to 4.0–4.5 with trichloroacetic acid, filter to remove the bacterial mass, adjust the filtrate pH to 6.0–6.5, add 95% ethanol, and precipitate hyaluronic acid. Dissolve the precipitate in a 0.1 mol/L sodium chloride solution, stirring, add an excess of 1% CPC to form a complex precipitate with the hyaluronic acid in the filtrate, let stand, siphon off the mother liquor, wash the precipitate twice, dissolve in 0.4 mol/L sodium chloride solution with stirring overnight, filter, precipitate with ethanol, dehydrate with ethanol, and vacuum dry to obtain hyaluronic acid.

Currently, the fermentation method for producing hyaluronic acid as an alternative to tissue extraction has become a trend. The fermentation method for producing hyaluronic acid has a simple process, does not rely on animal tissues, and its yield is not limited by raw material sources. Additionally, hyaluronic acid exists in a free state in the fermentation broth, making it easy to separate, purify, and industrialise. Therefore, the fermentation method has become the primary method for industrial production of hyaluronic acid [3].

1.3 метод искусственного синтеза

Related studies have shown that hyaluronic acid in living organisms is synthesised by hyaluronic acid synthase catalysing the reaction of UDP-G1cA and UDP-G1cNAc [4]. Therefore, researchers both domestically and internationally have attempted to synthesise hyaluronic acid in vitro using enzymatic methods and have made some progress. Neuman [5] reported a method for the artificial synthesis of hyaluronic acid, First, a polysaccharide polymer, one of the biological macromolecules, is used to synthesise hyaluronic acid oxazepane derivatives. Then, a decomposing enzyme (hyaluronidase from sheep or cow testes) is added to form a complex of the derivative and the enzyme. Finally, the enzyme is removed from the reaction solution, and hyaluronic acid is synthesised. Additionally, precipitation, separation, and purification are required.

Artificially synthesised hyaluronic acid is similar in quality to natural hyaluronic acid, but the precursor materials required for in vitro synthesis are expensive, so the artificial synthesis method is generally used for producing high-molecular-weight, high-purity hyaluronic acid [6].

2 исследования по производным гиалуроновой кислоты

Clinical applications have demonstrated that natural hyaluronic acid possesses excellent biocompatibility; however, it is easily degraded and diffused in tissues, resulting in short retention times in the body and suboptimal application outcomes. Recent studies have shown that hyaluronic acid derivatives obtained through modification and cross-linking can address these limitations [7].

The hydroxyl, carboxyl, N-acetylamino, and reducing ends of the hyaluronic acid molecule are the four sites susceptible to chemical modification, with primary modification methods including esterification, cross-linking, and grafting. The two most commonly used sites for covalent modification of hyaluronic acid are the carboxyl and hydroxyl groups. Currently reported derivatives with clinical application value are primarily new excipients derived from the modification of the hydroxyl and carboxyl groups of hyaluronic acid. 

These derivatives can be selected based on their intended use, with appropriate cross-linking agents chosen to enhance relevant physical properties such as biocompatibility, degradability, in vivo retention time, drug loading capacity, and stability. Hyaluronic acid gels modified with diethyl sulfoxide (DVS) exhibit unique biocompatibility and other properties, solutions using aldehydes as cross-linking agents (hyaluronic acid fluids) exhibit high viscoelasticity, while cross-linking agents with multiple functional groups, such as epoxy compounds, can improve water solubility. Additionally, the reaction between cross-linking agents and the carboxyl groups of hyaluronic acid can produce derivatives, such as esters and amines, which enhance biocompatibility, among other properties [8]. Furthermore, cross-linking reactions can be used to design and prepare functional, intelligent drug carriers, thereby enhancing drug efficacy, improving drug targeting, and reducing adverse effects. Therefore, the use of cross-linking reactions to modify hyaluronic acid not only expands its application scope but also enhances its practical value [9].

3 применения гиалуроновой кислоты порошка

3.1 применение в косметике

In the early 1980s, the excellent moisturising properties of hyaluronic acid garnered significant attention from the international cosmetics industry. Extensive literature and decades of domestic and international applications have demonstrated that hyaluronic acid can be used in cosmetics such as creams, lotions, masks, beauty serums, toners, lipsticks, foundations, and essences, as well as in products like shampoos, conditioners, mousses, and facial cleansers. For example, Restylane by Swiss company Restylane, Hydrobella moisturising lotion by French company Maybelline, and domestic brands such as Yongfang, Ziranmei, and Lvdanlan [10]. In cosmetics, hyaluronic acid plays a role in moisturising, preventing and repairing skin damage, nourishing and lubricating the skin, and having antibacterial and anti-inflammatory effects. Currently, for the rejuvenation of facial wrinkles, botulinum toxin and skin fillers are the two main non-surgical treatment methods, targeting dynamic and static wrinkles, respectively. Since hyaluronic acid was first used as a skin filler, its advantages and efficacy have gradually gained recognition from both medical professionals and patients, leading to a steady increase in usage. It has broken the dominance of collagen-based products and has ranked first in usage in the United States for five consecutive years [11].

3.2 применение в пищевой промышленности

In China, over 98% of hyaluronic acid is primarily used in the pharmaceutical, clinical diagnosis, and cosmetics industries. Hyaluronic acid is still in its infancy in the food sector, with limited reports available. In fact, hyaluronic acid is not only used topically for moisturisation; oral hyaluronic acid can also enhance the body's увлажнение. Через пищеварение и всасывание гиалуроновая кислота может повысить жизнеспособность и молодость; Он может увлажнять и сглаживать кожу, делая ее мягкой и эластичной; И это может задержать старение и предотвратить такие заболевания, как артрит, артериосклероз, аритмия и мозговая атрофия. Растет количество гиалуроновых кислотных добавок для красоты и здоровья, доступных как внутри страны, так и за рубежом, таких как Hyaron ECM·E, производимые японским институтом исследований гиалуроновой кислоты, косметические быстродействующие капсулы, производимые Natural-Max, гиалуроновые капсулы и таблетки, производимые естественными источниками, а также доступные внутри страны оральная красота коллаген гиалуроновой кислоты и Rui'. Капсулы источника воды er.

3.3 клиническое применение

Чистые гиалуроновые кислотные составыДоступны в трех формах для клинического применения: жидкое распыление, применение геля и пленка. Гиалуроновая кислота широко используется в офтальмологии и ортопедии и распространилась на многие другие области, включая общую хирургию, отоларингологию и ручную хирургию. Гиалуроновая кислота используется для лечения заболеваний костей и суставов, эффективно смягчая артрит, боль в суставах и регулируя функции суставов. Он также показал хорошие результаты в хирургии фиксации переломов, жесткости суставов, и поясничной дискоэктомии инъекционной терапии. Послеоперационное сцепление тканей является основной проблемой в хирургии. Обширные клинические испытания показали, что гиалуроновая кислота эффективно предотвращает послеоперационное адгезию, значительно сокращая осложнения и последствия адгезии. Поскольку гиалуроновая кислота является естественным компонентом человеческого и животного организма, она безопасна и надежна как фармацевтическое сырье без побочных эффектов. Поэтому гиалуроновая кислота сегодня является очень популярным биоматериалом в медицине.

Pang Suqiu et al. [12] used hyaluronic acid solution to treat dry eye syndrome, and clinical results indicated that hyaluronic acid has a good therapeutic effect on dry eye disease. Goto et al. [13] administered sodium hyaluronate into the joint cavities of 25 patients with chronic progressive joint diseases, and followed up with clinical symptoms and parameters. The results showed significant improvements in all indicators, with patients&#- 39; - условия улучшаются. Luo Hongtu et al. [14] случайным образом разделили 396 пациентов, проходящих различные операции на щитовидную железу, на две группы. Экспериментальная группа (214 случаев) получила инъекции гиалуроновой кислоты на поверхности раны щитовидной железы, глубоко в группу передних шейных мышц, глубокий слой плацизмы. Контрольная группа из 182 пациентов не получала гиалуроновую кислоту.

The results showed that 26 cases of postoperative adhesion occurred in the experimental group, while 41 cases occurred in the control group, with a significant difference between the two groups. Additionally, hyaluronic acid, as an important component of the extracellular matrix, regulates interactions between cells and between cells and the matrix, promoting wound healing and inhibiting abnormal scar formation caused by excessive collagen deposition. Hyaluronic acid also promotes granulation tissue formation, reduces scab area, shortens scab detachment time, and has a promoting effect on burn healing. Jiang Lixia et al. [8] reported that spraying burn patients with hyaluronic acid artificial skin powder resulted in good therapeutic effects and high safety.

3.4 применение в аптеке

3.4.1 повышение стабильности наркотиков

Freeze-dried single-chamber liposomes tend to reform into large multi-chamber liposomes, which is detrimental to therapies requiring small particle liposomes. Wang Yuhui [15] reported that by bonding sodium hyaluronic acid to the surface of biodegradable liposomes via hydrogen bonds, the transformation of freeze-dried single-chamber liposomes into large multi-chamber liposomes could be effectively inhibited, thereby stabilising freeze-dried single-chamber liposomes. Peer et al. [16] prepared hyaluronic acid-heparin conjugate gels and bound recombinant human basic fibroblast growth factor-2 (FGF-2) to the heparin end of the hyaluronic acid-heparin conjugate. In vitro analyses indicated that hyaluronic acid-heparin conjugate gels enhance the stability and activity of FGF-2.

3.4.2 применение в контролируемых составах

Hyaluronic acid and its derivatives can serve as sustained-release carriers for various drugs, such as anticancer drugs, anti-inflammatory drugs, and anaesthetics. Hyaluronic acid has diverse application forms as a drug carrier. Chou et al. [17] prepared hyaluronic acid-coated polycyanoacrylate butyl ester nanoparticles (hyaluronic acid-PBCA), which were obtained through a free radical polymerisation reaction of hyaluronic acid monomers and polycyanoacrylate monomers. Using paclitaxel as a model anticancer drug, the encapsulation efficiency of hyaluronic acid-PBCA nanoparticles reached 90%. The tumor cell proliferation inhibitory effect of paclitaxel-loaded hyaluronic acid-PBCA nanoparticles was significantly higher than that of paclitaxel-loaded PBCA nanoparticles and paclitaxel injection. Homma et al. [18] conjugated hyaluronic acid with the anti-inflammatory drug methotrexate using short peptides and linkers to form hyaluronic acid-methotrexate conjugates for the treatment of osteoarthritis, achieving controlled-release of the drug at the site of inflammation and effectively reducing the toxic side effects of methotrexate. Hyaluronic acid hn et al. [19] prepared injectable hyaluronic acid microgel for the controlled release of erythropoietin (EPO). In vivo release experiments showed that EPO was slowly released from the microgel, with plasma EPO concentrations exceeding 0.1 mg/L, which is the minimum concentration required for EPO to exert its effects. This concentration was maintained for 7 days without significant toxic side effects.

Hyaluronic acid and its derivatives as carriers offer unique biocompatibility, rheological properties, and chemical and physical diversity, making them an effective sustained-release system for pharmacologically active molecules. The practical application of hyaluronic acid as a biological carrier combined with various drugs will be a key focus of future research and development.

3.4.3 применение в противомалярийных препаратах

Research has shown that certain solid tumours and metastatic lymphocytes express high levels of hyaluronic acid receptors—CD44—with which hyaluronic acid has a strong affinity. As a targeted carrier for antitumour drugs, hyaluronic acid can bind smaller drug molecules to its network structure or graft drug molecules onto hyaluronic acid-based drug carriers, targeted binding with receptors on the surface of tumour cells, enabling more drug molecules to enter tumour tissue, increasing the absorption and retention time of anticancer drugs in tumours and lymph nodes, thereby enhancing drug efficacy and reducing toxic side effects. Luo et al. [20] esterified hyaluronic acid with paclitaxel to form a bio-targeted prodrug. Fluorescent labelling revealed that the drug could specifically bind to cells, and this binding could be blocked by excess hyaluronic acid and anti-CD44 antibodies but not by chondroitin sulfate. Paclitaxel was released through the hydrolysis of the ester bond. Brown et al. [21] administered 5-fluorouracil and methotrexine containing hyaluronic acid and without hyaluronic acid to nude mice with thymoma via tail vein injection, The results showed that the drug concentrations in the tumour tissue increased by 403% and 106%, respectively.

Hyaluronic acid and its derivatives can be formulated into drug compositions or used as carriers to target and retain different drugs in various parts of the human body. This not only enables drugs to act on more precise target sites, increasing the concentration of therapeutic drugs at the site of action and significantly enhancing therapeutic efficacy, but also avoids drug side effects, providing a more effective approach for disease treatment [22].

3.5 биоматериалы

As a biomaterial, hyaluronic acid possesses advantages such as good biocompatibility and rapid biodegradability. Chen Jianying et al. [23] conducted biocompatibility tests on cross-linked hyaluronic acid gel membranes (CIIA-gel) in terms of in vitro haemolysis, cytotoxicity, acute toxicity, eye irritation, intradermal reaction, sensitisation, and genotoxicity. The results demonstrated that CIIA-gel material exhibits excellent biocompatibility and stable physical and chemical properties. Xiao Rongdong et al. [24] conducted in vivo degradation tests on hyaluronic acid membranes, which conformed to the general process of biodegradation of biomaterials in vivo, with no significant inflammatory reactions and satisfactory tissue compatibility. Fan Hongbin, Hu Yunyu et al. [25] conducted experimental studies on gelatin-chondroitin sulfate-sodium hyaluronate as a tissue engineering cartilage scaffold, demonstrated that gelatin-chondroitin sulfate-sodium hyaluronate porous scaffolds prepared by vacuum drying at 80°C exhibit good pore size, porosity, and compressive load-bearing capacity, and show good compatibility with rabbit bone marrow mesenchymal stem cells (MSCs), making them a novel biomimetic scaffold material for cartilage tissue engineering.

4 анализ и резюме

In recent years, hyaluronic acid has developed rapidly. In 1985, the total global sales of hyaluronic acid in the international market reached 100 million USD, rising to over 200 million USD in 1990. By 2004, the global market size for hyaluronic acid applications was approximately 3 billion USD, and by 2012, it had grown to approximately 4.5 billion USD. Statistical data show that in 2012, the total sales of hyaluronic acid as a single skin filler in the international market reached 1.4 billion US dollars, with the markets for drug cosmetics and skincare products and medical products each accounting for half [26-28].

Гиалуроновая кислота нового типа обладает такими преимуществами, как хорошая биосовместимость, быстрая деградация, отличные увлажняющие свойства и стабильность тканей. Однако развитие гиалуроновой кислоты в китае по-прежнему сдерживается рядом проблем. Во-первых, Китай и#39;s production capacity for hyaluronic acid is far from meeting market demand, especially for high-molecular-weight pharmaceutical-grade hyaluronic acid, which must be imported from abroad. Therefore, increasing the molecular weight and production volume of hyaluronic acid is an urgent issue to address.

Second, the variety of hyaluronic acid derivatives is relatively limited, with similar physical and chemical properties, limiting the range of options available and necessitating further research and development. Third, there are no clear grading standards for hyaluronic acid, which is currently classified into food-grade, cosmetic-grade, and pharmaceutical-grade categories based on intended use. The criteria for these classifications are vague, and there is significant overlap between grades, causing significant inconvenience in practical applications. Fourth, when used as a drug carrier, there is no standard method for calculating drug loading capacity, which affects drug content and preparation processes. Fifth, the process of combining hyaluronic acid with other materials to produce biomaterials is still immature, with low production rates and currently at an early stage, requiring further research.

Кроме того, урожайность иquality of hyaluronic acid produced by microbial methods primarily depend on the following factors: the performance of the production strain, the culture medium, the optimisation of fermentation processes, and the control of fermentation and subsequent separation and purification [29-30]. In China, due to limitations in fermentation equipment, processes, and strain selection, the production level and efficiency of hyaluronic acid are relatively low compared to foreign countries, with imports being the primary source, especially for high-purity, high-molecular-weight hyaluronic acid. Due to these limitations, the price of hyaluronic acid in China remains high. However, with the increasing maturity of fermentation technology in China, growing health awareness, and improved understanding of hyaluronic acid, the market for food-grade hyaluronic acid has seen rapid expansion in recent years. In summary, whether for pharmaceutical, cosmetic, or food applications, hyaluronic acid holds vast development potential and demand.

Finally, it is hoped that through the joint efforts of domestic and international scholars, more innovative ideas and applications can be applied to hyaluronic acid research and development, ensuring that the comprehensive development of hyaluronic acid is just around the corner.

Ссылки на статьи

[1] бай хюйю, сюй цзинь, ли хюйцзюнь и др. Ход исследований по подготовке и применению гиалуроновой кислоты [J]. Химическая промышленность провинции гуандун, 2010, 37(11): 332.

[2] сон лей, ван тенгфей. Обзор текущего состояния исследований гиалуроновой кислоты [J]. Журнал шаньдунского колледжа легкой промышленности, 2012, 26(2): 78.

[3] чен ихан, е руй, цянь юэ и др. Научно-исследовательский прогресс в области биохимического производства гиалуроновой кислоты [J]. Журнал шанхайского института прикладных технологий, 2012, 12(2): 1124.

[4] Valarie L, Bruce A. очистка и липидовая зависимость рекомбинантных гиалуронанских синтазов от Streptococcus pyogenes и Streptococcus equisimilis [J]. J Biol Chem, 1999, 274(7):4239.

[5] Neuman MG, Orua L, Coto G и др. Сигналы гиалуроновой кислоты для восстановления при индуцированном этанолом апоптозе клеток кожи in vitro [J]. Клин биохем, 2010, 43 (10/11): 822.

[6] Ozgenel G, Et6z A. влияние повторных инъекций гиалуроновой кислоты на перитендные соединения после ремонта сухожилий flexor: предварительное рандомизированное клиническое исследование под контролем плацебо [J]. Ulus Travma Acil Cerrahi Derg, 2012, 18(1): 11.

[7] Balazs E A, Laurent T C. круглый стол discussion: новые приложения для hyaluronan [A]. Лоран т. с. химия, биология и медицинское применение гиалуронана и его производных [м]. Лондон: Portland Press, 1998: 325.

[8] Jiang Lixia, Wang Wenbin. Применение гиалуроновой кислоты и ее производных в медицине [J]. Китайский журнал восстановительной хирургии, 2010, 14(15): 56.

[9] сюй синь, ши даньпин, е вэньси и др. Прогресс в подготовке взаимосвязанных производных гиалуронанов [J]. Химическая промышленность гуандуна, 2012, 39(5): 99.

[10] Пан хонгмей. Обзор текущего состояния hyaluronan research [J]. Питание и ферментация сычуана, 2003, 1(8): 67.

[11] у суфан. Базовые знания и клиническое применение гиалуроновой кислоты [J]. Современная практическая медицина, 2010, 22(4): 171.

[12] Пан суцю, чжоу цзиньшень, чэнь цюсюань и др. Клиническое применение гиалуроната натрия [J]. Straits Pharmacy, 2011, 15(4): 252.

[13] гото м, ханю т, йошио т и др. Внутрисуставная инъекция гиалуроната (SI-6601D) улучшает боль в сустагланде и уровень простагландиновой синиальной жидкости E2 при ревматоидном артрите: многоцентровое клиническое исследование [J]. Clin Exp Rheumatol, 2001, 19(4): 377.

[14] Лу хунту, ян шао ю. Исследование профилактического воздействия гиалуроната натрия на послеоперационные адгезии после операции на щитовидной железе [J]. Журнал клинической хирургии, 2009, 12(5): 313.

[15] ван юхуэй. Применение гиалуроновой кислоты и солей натрия в фармацевтических препаратах [J]. Продукты питания и медикаменты, 2011, 7(8): 78.

[16] ян хао, сян вэньшуо, ин гоцин и др. Подготовка и применение взаимосвязанных производных гиалуроновой кислоты [J]. Прогресс химической промышленности, 2006, 5(9): 234.

[17] чу у й, ко й й, ван фу и др. Эффект лечения гиалуроната натрия на повреждения плеча без полных разрывов: рандомизированное, двойное ослепление, плацебо-контролируемое исследование [J]. Журнал хирургии плеча и локтя, 2010, 19(4): 557.

[18] хомм а, сато х, тамура т и др. Синтез и оптимизация гиалуронических кислотно-метотрексатных соединений для получения максимальной пользы при лечении остеоартрита [J]. Биоорганическая и Медицинская химия, 2010, 18(3): 1062.

[19]Hahn S, Kim JS, Shimoboujit H. инъецируемые гиалуроновая кислота микрогидрогели для контролируемого выделения эритропойтина [J]. J биомед матер Res A, 2007, 80(4): 916.

[20]Luo Y, Ziebell M R, Prestwich G. Биоакромолекулы, 2000, 1(2): 208.

[21]Brown T J, Hatherell E M, Falzon J L, et al. Гиалуронань нацеливание антиметаболитных противораковых препаратов на Рак молочной железы человека ксенотрансплантация [Z]. (2005) введен в Рак Chemother Pharmacol.

[22] Liu Z, Wang B. новые достижения в клинических исследованиях гиалуроновой кислоты [J]. Продукты питания и медикаменты, 2006, 8(12): 98.

[23] чэнь цзянин, сон хайбо. Подготовка и исследование биосовместимости взаимосвязанных гиалуронанских гелевых мембран [J]. Биомедицинские инженерные исследования, 2009, 28(2): 104.

[24] сяо ронгдон, вэнь госин. Сравнение механических свойств и тканевой совместимости мембран коллагена/гиалуронана и гелятиновых губчатых лесов [J]. Китайский журнал тканевых исследований, 2012, 16(25): 1123.

[25] фан хунбин, юн ю. Экспериментальное исследование гелятина-хондроитина сульфата-гиалуроната натрия в качестве хрящевых лесов тканевой инженерии [J]. Китайский журнал восстановительной хирургии, 2005, 19(6): 473.

[26] Chou CL, Li HW, Lee SH и др. Эффект внутрисуставной инъекции гиалуроновой кислоты у пациентов с ревматоидным артритом коленного сустава [J]. Журнал китайской медицинской ассоциации, 2008, 71(8): 411.

[27]Lee H, Lee K, Park TG. Гиалуроническая кислота -paclitaxel conjugate micelles: синтез, характеристика и антиопухолевая активность [J]. Биохимия, 2008, 19(6): 1319.

[28]Benjamin Y S O, Ranganath S H, Lee L Y, et al. Поставка Paclitaxel из PLGA пеноматериалов для контролируемого высвобождений в послехирургической химиотерапии против глиопастомы multiforme [J]. Биоматериалы, 2009, 30(12): 3189.

[29]Park K, Lee M Y, Kim K S и др. Лечение опухоли по конкретным целям вегф сирна сочетается с податливой полиэтиленеминовой гиалуроновой кислотой [J]. Биоматериалы, 2010, 31(19): 5258.

[30] судхир х, йилонг ф, дэвис и др. Использование субмикрокро-наноплантатов PLGA для доставки паклитакселя с усиленной фармакокинетикой и терапевтической эффективностью при внутричерепной глиоме мышей [J]. Биоматериалы, 2010, 31(3): 5199.